RESUMO
11β-Hydroxysteroid dehydrogenase (11β-HSD) is a metabolic enzyme of glucocorticoid. Growing evidence suggests that inhibiting over-expression of 11β-HSD1 and reducing partial effects of glucocorticoid could be the strategy to treat type 2 diabetes, as well as metabolic syndrome. Researching and developmenting selective 11β-HSD1 inhibitors may become a new direction. As natural products (NPs) have represented a cornerstone of pharmaceutical research, literatures on the development of natural products with selective inhibition against 11β-HSD1 published during the last 10 years were selected, and the inhibitors were classified according to the way how to find them. This paper will provide reference for the further research on the selective 11β-HSD1 inhibitors.